相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Validating Whole Slide Imaging Systems for Diagnostic Purposes in Pathology Guideline Update From the College of American Pathologists in Collaboration With the American Society for Clinical Pathology and the Association for Pathology Informatics
Andrew J. Evans et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2022)
Ovarian cancer immunogenicity is governed by a narrow subset of progenitor tissue-resident memory T cells
Carmen M. Anadon et al.
CANCER CELL (2022)
Individualization in the first-line treatment of advanced ovarian cancer based on the mechanism of action of molecularly targeted drugs
Hidekatsu Nakai et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2022)
Deep learning-based histotype diagnosis of ovarian carcinoma whole-slide pathology images
Hossein Farahani et al.
MODERN PATHOLOGY (2022)
Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types
Shiro Takamatsu et al.
JCO PRECISION ONCOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39)
Kathleen N. Moore et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Signatures and Specificity of Tissue-Resident Lymphocytes Identified in Human Renal Peritumor and Tumor Tissue
Theresa Dornieden et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2021)
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
Bradley J. Monk et al.
LANCET ONCOLOGY (2021)
Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
Hisamitsu Takaya et al.
SCIENTIFIC REPORTS (2020)
Development and Validation of a Deep Learning Algorithm for Gleason Grading of Prostate Cancer From Biopsy Specimens
Kunal Nagpal et al.
JAMA ONCOLOGY (2020)
Pitfalls in assessing stromal tumor infiltrating lymphocytes (sTILs) in breast cancer
Zuzana Kos et al.
NPJ BREAST CANCER (2020)
Tissue-resident memory-like T cells in tumor immunity: Clinical implications
Madhav Dhodapkar et al.
SEMINARS IN IMMUNOLOGY (2020)
Deep learning-based cross-classifications reveal conserved spatial behaviors within tumor histological images
Javad Noorbakhsh et al.
NATURE COMMUNICATIONS (2020)
International Endocervical Adenocarcinoma Criteria and Classification Validation and Interobserver Reproducibility
Anjelica Hodgson et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2019)
The mesenchymal transition subtype more responsive to dose dense taxane chemotherapy combined with carboplatin than to conventional taxane and carboplatin chemotherapy in high grade serous ovarian carcinoma: A survey of Japanese Gynecologic Oncology Group study (JGOG3016A1)
Ryusuke Murakami et al.
GYNECOLOGIC ONCOLOGY (2019)
Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial
Andrew R. Clamp et al.
LANCET (2019)
GOnet: a tool for interactive Gene Ontology analysis
Mikhail Pomaznoy et al.
BMC BIOINFORMATICS (2018)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Tumor Microvessel Density as a Potential Predictive Marker for Bevacizumab Benefit: GOG-0218 Biomarker Analyses
Carlos Bais et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2017)
Bevacizumab May Differentially Improve Ovarian Cancer Outcome in Patients with Proliferative and Mesenchymal Molecular Subtypes
Stefan Kommoss et al.
CLINICAL CANCER RESEARCH (2017)
Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes
Ryusuke Murakami et al.
AMERICAN JOURNAL OF PATHOLOGY (2016)
Prediction of taxane and platinum sensitivity in ovarian cancer based on gene expression profiles
Ryusuke Murakami et al.
GYNECOLOGIC ONCOLOGY (2016)
Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study
Russell Vang et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2016)
Development and Validation of a Histological Method to Measure Microvessel Density in Whole-Slide Images of Cancer Tissue
Koen M. Marien et al.
PLOS ONE (2016)
A VEGF-dependent gene signature enriched in mesenchymal ovarian cancer predicts patient prognosis
Xia Yin et al.
SCIENTIFIC REPORTS (2016)
Evidence for a Dualistic Model of High-grade Serous Carcinoma BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma
Brooke E. Howitt et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
The Molecular Signatures Database Hallmark Gene Set Collection
Arthur Liberzon et al.
CELL SYSTEMS (2015)
The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
R. Salgado et al.
ANNALS OF ONCOLOGY (2015)
Risk Prediction for Late-Stage Ovarian Cancer by Meta-analysis of 1525 Patient Samples
Markus Riester et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Validating Whole Slide Imaging for Diagnostic Purposes in Pathology Guideline from the College of American Pathologists Pathology and Laboratory Quality Center
Liron Pantanowitz et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2013)
Identification and Analysis of In Vivo VEGF Downstream Markers Link VEGF Pathway Activity with Efficacy of Anti-VEGF Therapies
MJ Brauer et al.
CLINICAL CANCER RESEARCH (2013)
Long-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trial
Noriyuki Katsumata et al.
LANCET ONCOLOGY (2013)
Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma
Robert A. Soslow et al.
MODERN PATHOLOGY (2012)
Integrated genomic analyses of ovarian carcinoma
D. Bell et al.
NATURE (2011)
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer
Robert A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Timothy J. Perren et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
The histologic type and stage distribution of ovarian carcinomas of surface epithelial origin
JD Seidman et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY (2004)
Statistical methods for ranking differentially expressed genes
P Broberg
GENOME BIOLOGY (2003)
分享论文
